---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000088"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:08.603464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track

## Summary
- Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.
- Obe-cel PDUFA target action date set at November 16, 2024; BLA under review by FDA.
- FELIX data (median follow-up 21 mos): 40% of responders in ongoing remission without subsequent stem cell transplant.
- MAA submitted to UK MHRA July 2024; EMA MAA accepted April 2024.
- R&D expenses $36.6M, G&A $21.9M, both up on pre-commercialization activities and new manufacturing facility.

## SEC filing metadata
- accession: 0001730463-24-000088
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000088/0001730463-24-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000088/autl-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000088
- JSON: https://secwatch.observer/filing/0001730463-24-000088.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.